Atlas Trials

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Clinical trial NCT05437120 · COMPLETED

Trial details

NCT number
NCT05437120
Sponsor
Vertex Pharmaceuticals Incorporated
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2022-07-22
Primary completion
2023-03-16
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.